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International Analysis of Age-Specific
Mortality Rates From Mesothelioma
on the Basis of the International
Classification of Diseases, 10th Revision
abstract
Past analyses of mortality data frommesothelioma relied on unspecific codes, such as pleural neoplasms.
We calculated temporal trends in age-specific mortality rates in Canada, the United States, Japan, France,
Germany, Italy, the Netherlands, Poland, the United Kingdom, and Australia on the basis of the 10th version
of the International Classification of Diseases, which includes a specific code for mesothelioma. Older age
groups showed an increase (in the United States, a weaker decrease) during the study period, whereas in
young age groups, there was a decrease (in Poland, a weaker increase, starting, however, from low rates).
Results were consistent between men and women and between pleural and peritoneal mesothelioma,
although a smaller number of events in women and for peritoneal mesothelioma resulted in less precise
results. The results show the heterogeneous effect of the reduction of asbestos exposure on different age
groups; decreasing mortality in young people reflects reduced exposure opportunity, and increasing
mortality in the elderly shows the long-term effect of early exposures.
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Descriptive cancer epidemiology relies on data on
cancer incidence, typically frompopulation-based
cancer registries, and cancer mortality, typically
from national statistics.1 Data from cancer regis-
tries are of better quality because they include
histologic verification of most of the patients; how-
ever, in the case of rare neoplasms, they are
limited by the relatively small size of many cancer
registries. Mortality data rely on medical certifica-
tion inmost countries, whose diagnostic accuracy
is suboptimal.2
Because the occurrence of mesothelioma is rela-
tively rare in most populations, its descriptive
epidemiology is largely based on mortality data,3
which are coded on the basis of subsequent
versions of the International Classification of Dis-
eases (ICD).4 Until the 10th revision of the ICD
(ICD10), however, mesothelioma was not associ-
ated with a specific code, and mesothelioma
deaths were classified under neoplasms of the
pleura (ICD, 9th revision [ICD9] code 163), neo-
plasms of the peritoneum (ICD9 code 158), and
under other organs, such as the pericardium and
the tunica vaginalis, where mesothelioma rarely
occurs. Other tumor types were also included in
these rubrics, complicating the use of mortality
data todescribegeographicand temporal patterns
of the disease.
In ICD10,5 a specific code was introduced for
mesothelioma (fromany site),whichenablesmore
valid analyses ofmortality data frompopulations in
which the new classification has been adopted;
this occurred in the late 1990s and early 2000s in
many high-income countries. Because mortality
data on the basis of ICD10 have become available
for a period of> 15 years in several countries, we
aimed to analyze international temporal patterns
of age-adjusted and age-specific trends in meso-
thelioma mortality.
The WHO database (WHO Statistical Information
System) provides official death certification data
for most cancer sites; we considered those for
mesothelioma from the first year of use of the
ICD10 until the most recent year. We restricted
the analysis to selected high-income countries
providing valid and consistent data on mesothe-
lioma and at least 15 million inhabitants (Canada
[2000-2011], the United States [1999-2014],
Japan [1995-2013],France [2000-2013],Germany
[1998-2014], Italy [2003-2012], the Netherlands
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[1996-2013], Poland [1999-2014], the United
Kingdom [2001-2013], and Australia [1998-
2014]). We considered deaths from all meso-
thelioma (ICD10 C45), as well as from pleural
mesothelioma (ICD10 C45.0) and peritoneal
mesothelioma (ICD10 C45.1). In the latter anal-
ysis, we attributed deaths from mesothelioma
from unspecified sites (ICD10 C45.9) to the
pleura (85% in men, 73% in women) and peri-
toneum (7% in men, 18% in women) on the
basis of the distribution of the patients registered
in the SEER program during 2003 to 2008.6
We computed age-specificmortality rates for each
5-year age group (from0-4 to> 85 years) for each
year and for the periods 2000 to 2004, 2005 to
2009, and 2013 (or closest available year, 2011 in
Canada, and 2012 in Italy). We calculated age-
standardized rates (world standard population)
per 100,000 men and women, at all ages, using
the direct method, as well as for the age groups
35 to 54, 55 to 64, 65 to 74 and> 75 years.7 We
also fit a logarithmic Poisson count data joinpoint
regression model to identify trend changes for all
ages and each age group.8
Mortality rates for all mesotheliomas are reported
in Figure 1; average annual percent changes are
listed in Table 1; overall age-standardized rates in
2000 to 2004 and in 2013 are reported in Appen-
dix Table A1, and detailed results of the joinpoint
analysis are reported in Appendix Table A2. In
2000 to 2004, rates inmenwere.2of 100,000 in
the Netherlands, United Kingdom, and Australia;
between 1.0 and 1.3 of 100,000 in France, Ger-
many, and Italy; approximately 0.7 of 100,000 in
Canada and the United States; and , 0.5 of
100,000 in Japan and Poland. In 2013, overall
rates tended to decrease in the Netherlands,
Australia, the United States, and France (and
to a small extent, in the United Kingdom) and
tended to increase in Japan and mostly in Poland
(to reach 0.6 of 100,000). Overall female rates
were lower, between 0.1 and 0.5 of 100,000, the
highest one in 2000 to 2004 being in Italy, the
United Kingdom, and Australia. No appreciable
change was observed between 2000 to 2004 and
2013, except in Poland, whose rates rose from
0.07 to 0.21 of 100,000; a small increase was
apparent in the United Kingdom and Australia
as well.
The analysis by age group among men showed a
consistent pattern in most countries in the anal-
ysis: older age groups showed an increase (in the
United States, a weaker decrease) in mortality
rates during the period of study, whereas in young
age groups, there was a decrease (in Poland, a
weaker increase). The magnitude of the increase
(in older age groups) or the decrease (in younger
age groups) varied across countries, as it varied
the years in which changes in trends were iden-
tified by the joinpoint analysis.
The results of the age-specific analysis among
women revealed a pattern similar to that identified
among men, with mortality trends being negative
(or less positive) in the young and positive (or less
negative) in the elderly, although in some of the
countries (eg, Germany), this shift from negative
across age groups was not monotonic, and the
absolute value of the change varied across
countries.
We repeated the analysis separating pleural and
peritoneal mesothelioma (Appendix Figs A1 and
A2; Appendix Table A3). Because pleural me-
sothelioma deaths represented the vast majority
of the total, trends andpatterns for this formof the
disease paralleled those of the main analysis.
The assessment of trends of peritoneal mesothe-
lioma among patients younger than 55 years of
age was hampered by a small number of deaths;
in the other age groups, however, patterns were
similar to those observed for all forms of the
disease.
The analysis of trends in mortality from mesothe-
lioma on the basis of ICD10 showed variability in
the absolute levels and in the presence and mag-
nitude of an increasing (or decreasing) trend.
Despite this heterogeneity, a consistent pattern
was shown in that mesothelioma rates were de-
creasing among younger people, whereas they
were still increasing among older people. The only
countries with a different pattern were the United
States (decrease in all age groups among men)
and Poland (increase in all age group and both
sexes).
The trends in age-adjusted rates are consistent
with those reported in recent years for individual
countries on the basis of either mortality or in-
cidence data, for example, Australia,9 Germany,10
the United States,6 and England.11 An analysis of
temporal trends in age-specific rates, however,
was reported only for 1998 to 2002 in southeast
England12; its results were similar to ours, al-
though on the basis of small numbers.
The decreases observed in the United States as
contrasted with western Europe were already ob-
served in an analysis of trends between 1973 and
200313 and in an age-period-cohort analysis of
trends until the end of last century,14 and are
attributable to earlier control of asbestos (mainly
2 jgo.org JGO – Journal of Global Oncology
Downloaded from ascopubs.org by 195.31.104.74 on August 21, 2017 from 195.031.104.074
Copyright © 2017 American Society of Clinical Oncology. All rights reserved.
All Ages
Canada4
3
2
1
0
AS
R
1995 2000 2005 2010 2015
Year
4
3
2
1
0
United States
AS
R
1995 2000 2005 2010 2015
Year
2015
4
3
2
1
0
Japan
AS
R
1995 2000 2005 2010
Year
4
3
2
1
0
France
AS
R
1995 2000 2005 2010 2015
Year
4
3
2
1
0
Germany
AS
R
1995 2000 2005 2010 2015
Year
4
3
2
1
0
AS
R
1995 2000 2005 2010 2015
Year
Italy 4
3
2
1
0
AS
R
1995 2000 2005 2010 2015
Year
Netherlands 4
3
2
1
0
AS
R
1995 2000 2005 2010 2015
Year
Poland 4
3
2
1
0
AS
R
1995 2000 2005 2010 2015
Year
United Kingdom 4
3
2
1
0
AS
R
1995 2000 2005 2010 2015
Year
Australia
2.0
1.0
0.0
AS
R
1995 2000 2005 2010 2015
Year
Italy 2.0
1.0
0.0
AS
R
1995 2000 2005 2010 2015
Year
Netherlands 2.0
1.0
0.0
AS
R
1995 2000 2005 2010 2015
Year
Poland 2.0
1.0
0.0
AS
R
1995 2000 2005 2010 2015
Year
United Kingdom 2.0
1.0
0.0
AS
R
1995 2000 2005 2010 2015
Year
Australia
2.0
1.0
0.0
AS
R
1995 2000 2005 2010 2015
Canada 2.0
1.0
0.0
AS
R
1995 2000 2005 2010 2015
United States 2.0
1.0
0.0
AS
R
1995 2000 2005 2010 2015
Japan 2.0
1.0
0.0
AS
R
1995 2000 2005 2010 2015
France 2.0
1.0
0.0
AS
R
1995 2000 2005 2010 2015
Year Year Year Year Year
Germany
35 to 54 Years
15
10
5
0
AS
R
1995 2000 2005 2010 2015
Year
Italy 15
10
5
0
AS
R
1995 2000 2005 2010 2015
Year
Netherlands 15
10
5
0
AS
R
1995 2000 2005 2010 2015
Year
Poland 15
10
5
0
AS
R
1995 2000 2005 2010 2015
Year
United Kingdom 15
10
5
0
AS
R
1995 2000 2005 2010 2015
Year
Australia
15
10
5
0
AS
R
1995 2000 2005 2010 2015
Year
Canada 15
10
5
0
AS
R
1995 2000 2005 2010 2015
Year
United States 15
10
5
0
AS
R
1995 2000 2005 2010 2015
Year
Japan 15
10
5
0
AS
R
1995 2000 2005 2010 2015
Year
France 15
10
5
0
AS
R
1995 2000 2005 2010 2015
Year
Germany
55 to 64 Years
30
20
10
0
AS
R
1995 2000 2005 2010 2015
Year
Italy 30
20
10
0
AS
R
1995 2000 2005 2010 2015
Year
Netherlands 30
20
10
0
AS
R
1995 2000 2005 2010 2015
Year
Poland 30
20
10
0
AS
R
1995 2000 2005 2010 2015
Year
United Kingdom 30
20
10
0
AS
R
1995 2000 2005 2010 2015
Year
Australia
30
20
10
0
AS
R
1995 2000 2005 2010 2015
Year
Canada 30
20
10
0
AS
R
1995 2000 2005 2010 2015
Year
United States 30
20
10
0
AS
R
1995 2000 2005 2010 2015
Year
Japan 30
20
10
0
AS
R
1995 2000 2005 2010 2015
Year
France 30
20
10
0
AS
R
1995 2000 2005 2010 2015
Year
Germany
65 to 74 Years
40
20
0
AS
R
1995 2000 2005 2010 2015
Year
Italy
40
20
0
AS
R
1995 2000 2005 2010 2015
Year
Netherlands
40
20
0
AS
R
1995 2000 2005 2010 2015
Year
Poland
40
20
0
AS
R
1995 2000 2005 2010 2015
Year
United Kingdom
40
20
0
AS
R
1995 2000 2005 2010 2015
Year
Australia
40
20
0
AS
R
1995 2000 2005 2010 2015
Year
Canada
AS
R 40
20
0
1995 2000 2005 2010 2015
Year
United States
AS
R 40
20
0
1995 2000 2005 2010 2015
Year
Japan
AS
R 40
20
0
1995 2000 2005 2010 2015
Year
France
AS
R 40
20
0
1995 2000 2005 2010 2015
Year
Germany
≥ 75 Years
Fig 1. Mesotheliomamortality rates on thebasis of International Classification ofDiseases, 10thRevision, by gender, in selectedcountries, for all ages, and
by age group. ASR, age-standardized rate per 100,000. Men, squares; women, circles.
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amphibole) exposure in the United States than in
other high-income countries. Japan had relatively
low rates in middle-aged and elderly people in the
early 2000s, but showed appreciable increases over
the calendar period considered, reflecting changes
in asbestos imports in the past in that country.15
Poland started from extremely low rates, whichwere
probably real, because the validity of Polish cancer
death certification has long been acceptable.16
Mesothelioma mortality rates were low in Eastern
compared with Western Europe,14 but show a
tendency toward leveling or even overcoming
western European rates in younger generations.
This likely reflects thechangingpattern and typeof
asbestos exposure in this region of the world.
Given the strong relationship between asbestos
exposure (mainly at the workplace) and occur-
rence of mesothelioma,17 and the fact that the
prevalenceof occupational exposurehasdeclined
in the last decades because of stricter regulations
on asbestos use,18 it is plausible that the results of
our analysis represent the effect of reduction of
asbestos exposure in the younger age groups. The
decline in mortality rates among young people
shows the benefit of reduced opportunity to expe-
rience occupational exposure throughout the
working life; in fact, these people were born ap-
proximately in the 1950s and started their working
life in the 1970s and 1980s, when restrictive
asbestos regulations were implemented. How-
ever, trends in the young age groups should be
interpreted with caution because of the small
number of deaths in this category. People ages
55 to74years, however, hadahigherprobability of
exposure during the early part of their working his-
tory, whereas those> 75 years of age experienced
the full extent of the epidemic of asbestos exposure,
at least during the first part of their employment
experience. This interpretation is consistent with a
predominant role of early exposure to asbestos in
determining subsequent risk of mesothelioma and
with a modest role of subsequent quitting or con-
tinuing exposure.19 These results also show the
powerful effect of measures aimed at preventing
asbestos exposure, which have been implemented
during the last decades: 2013mortality rates inmen
ages 35 to 54 years were, in most countries, in the
range 0.15 to 0.30 of 100,000, a level well below
thosemeasured a decade earlier, and the decline is
likely to continue in the coming years.
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Fig A1. Pleural mesothelioma mortality rates on the basis of the International Classification of Diseases (10th revision) codes by gender in selected
countries, by all ages, and by age group. ASR, age-standardized rate per 100,000. Men, squares; women, circles.
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Fig A2. Peritoneal mesothelioma mortality rates on the basis of the International Classification of Diseases (10th revision) codes by gender in selected
countries, by all ages, and by age group. ASR, age-standardized rate per 100,000. Men, squares; women, circles.
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Table A1. Mortality Rates per 100,000 From Mesothelioma at all Ages and by Age Group, by Gender, in Selected Countries Around 2002 (2000-2004),
2007 (2005-2009), and in 2013 (or the last available), and Corresponding Change in Rates
Age
(years) Country
Men Women
2002 2007 2013
Deaths, %
Change
2013
% Change
(2013/
2002) 2002 2007 2013
Deaths, %
Change
2013
% Change
(2013/
2002)
All ages Canada 1.14 1.19 1.07 359 26.1 0.20 0.20 0.21 71 5.0
United States 0.91 0.81 0.63 1911 230.8 0.17 0.17 0.17 586 0.0
Japan 0.50 0.59 0.65 1121 30.0 0.12 0.11 0.12 289 0.0
France 1.19 1.17 1.00 732 216.0 0.26 0.28 0.24 242 27.7
Germany 1.13 1.10 1.09 1157 23.5 0.25 0.22 0.23 297 28.0
Italy 1.42 1.49 1.50 1088 5.6 0.53 0.45 0.46 430 213.2
Netherlands 2.73 2.62 2.31 419 215.4 0.35 0.32 0.28 62 220.0
Poland 0.23 0.32 0.64 191 178.3 0.08 0.14 0.23 95 187.5
United Kingdom 2.96 3.00 2.86 2060 23.4 0.43 0.48 0.49 411 14.0
Australia 2.72 2.50 2.27 537 216.5 0.43 0.49 0.48 119 11.6
35-54 Canada 0.41 0.26 0.17 10 258.5 0.17 0.10 0.10 6 241.2
United States 0.27 0.18 0.15 74 244.4 0.11 0.11 0.10 48 29.1
Japan 0.35 0.32 0.32 55 28.6 0.09 0.08 0.10 16 11.1
France 0.54 0.36 0.16 15 270.4 0.14 0.13 0.07 6 250.0
Germany 0.49 0.32 0.26 37 246.9 0.13 0.13 0.06 9 253.8
Italy 0.89 0.51 0.33 31 262.9 0.45 0.25 0.20 19 255.6
Netherlands 0.98 0.50 0.55 15 243.9 0.28 0.20 0.05 1 282.1
Poland 0.24 0.30 0.40 22 66.7 0.11 0.13 0.18 10 63.6
United Kingdom 0.98 0.67 0.27 25 272.4 0.23 0.20 0.19 19 217.4
Australia 0.91 0.62 0.19 6 279.1 0.27 0.34 0.30 10 11.1
55-64 Canada 4.40 3.55 2.34 44 246.8 0.73 0.57 0.91 17 24.7
United States 2.43 1.95 1.39 228 242.8 0.50 0.50 0.54 98 8.0
Japan 1.82 2.14 1.97 174 8.2 0.35 0.34 0.35 31 0.0
France 3.99 3.33 2.61 101 234.6 1.00 0.80 0.62 26 238.0
Germany 4.09 3.15 2.14 109 247.7 0.89 0.71 0.59 32 233.7
Italy 5.34 5.33 3.68 131 231.1 2.04 1.46 1.25 48 238.7
Netherlands 9.21 7.28 6.37 68 230.8 1.08 1.12 0.74 8 231.5
Poland 0.88 1.15 2.68 67 204.5 0.28 0.56 0.87 25 210.7
United Kingdom 11.44 9.54 6.41 226 244.0 1.74 1.80 0.95 35 245.4
Australia 8.86 6.94 4.16 53 253.0 1.50 1.56 1.28 17 214.7
65-74 Canada 8.34 9.75 8.50 112 1.9 1.45 1.77 1.57 20 8.3
United States 6.92 6.31 5.06 565 226.9 1.12 1.25 1.24 152 10.7
Japan 3.16 4.11 5.14 404 62.7 0.77 0.65 0.79 67 2.6
France 9.17 9.88 7.29 192 220.5 1.95 2.41 1.77 54 29.2
Germany 8.67 9.71 9.63 427 11.1 1.71 1.49 2.12 104 24.0
Italy 9.73 12.21 14.07 429 44.6 3.16 3.35 3.85 133 21.8
Netherlands 23.21 24.41 18.26 147 221.3 2.54 2.09 2.71 23 6.7
Poland 1.41 2.22 4.72 60 234.8 0.46 0.91 1.66 29 260.9
United Kingdom 23.12 25.76 25.79 754 11.5 2.98 3.60 4.48 142 50.3
Australia 20.74 20.58 19.12 177 27.8 2.97 3.43 3.27 31 10.1
(Continued on following page)
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Table A1. Mortality Rates per 100,000 From Mesothelioma at all Ages and by Age Group, by Gender, in Selected Countries Around 2002 (2000-2004),
2007 (2005-2009), and in 2013 (or the last available), and Corresponding Change in Rates (Continued)
Age
(years) Country
Men Women
2002 2007 2013
Deaths, %
Change
2013
% Change
(2013/
2002) 2002 2007 2013
Deaths, %
Change
2013
% Change
(2013/
2002)
> 75 Canada 13.98 17.42 18.91 191 35.3 1.69 2.08 1.74 28 3.0
United States 14.72 13.72 10.49 1043 228.7 2.06 2.00 2.05 285 20.5
Japan 5.51 6.77 8.09 487 46.8 1.54 1.47 1.76 175 14.3
France 14.36 16.09 19.17 423 33.5 2.59 3.18 4.25 156 64.1
Germany 12.27 14.17 18.81 584 53.3 2.57 2.69 2.96 151 15.2
Italy 15.08 16.81 20.46 494 35.7 4.79 5.06 6.00 229 25.3
Netherlands 30.02 35.07 38.02 189 26.6 3.24 3.80 3.93 30 21.3
Poland 1.26 2.44 4.69 41 272.2 0.39 0.81 1.82 31 366.7
United Kingdom 32.96 39.41 49.65 1054 50.6 4.12 5.18 7.15 214 73.5
Australia 37.93 38.47 46.93 301 23.7 5.09 5.76 7.19 61 41.3
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